Extracellular matrix remodeling is a hallmark of pathological left ventricular (LV) hypertrophy and heart failure. This process is tightly controlled by the degrading matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). We hypothesized that circulating MMP-9 and TIMP-1 levels are altered already in persons with the signs of LV remodeling that forego clinical heart failure.
Design
Cross-sectional study in the Prospective Investigation of the Vasculature in Uppsala Seniors, a community-based cohort of 891 70-year-old men and women free from valvular disease, heart failure, and myocardial infarction.
Methods
We examined relations of serum MMP-9 and TIMP-1 to echocardiographic LV geometry and function. All models were adjusted for sex, height, intra-arterial systolic and diastolic blood pressures, antihypertensive medication use, and serum freezer time.
Results
Serum TIMP-1 was positively related to LV mass and wall thickness (r=0.15, P < 0.0001 and r =0.16, P < 0.0001, respectively), with a 32 g higher LV mass and 2.2 mm thicker walls in the fourth compared with the first quartile of serum TIMP-1. Serum TIMP-1 was also inversely related to LV ejection fraction (r = −0.10, P = 0.009), but not to LV dimension or diastolic function indices. Serum MMP-9 was only weakly related to LV wall thickness and isovolumic relaxation time (r =0.08, P =0.04 and r = −0.08, P = 0.04).
Conclusion
In this large population-based sample, serum TIMP-1 levels were related to LV mass, wall thickness, and inversely to systolic function. This may imply that extracellular matrix remodeling is involved already in the earliest stages of the process leading to heart failure.
SundstromJVasanRS.Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol2006; 17:45–53.
2.
SundstromJEvansJCBenjaminEJLevyDLarsonMGSawyerDB. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J2004; 25:1509–1516.
3.
SundstromJEvansJCBenjaminEJLevyDLarsonMGSawyerDB. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham heart study. Circulation2004; 109:2850–2856.
4.
WangTJLarsonMGBenjaminEJSiwikDASafaRGuoCY. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J2007; 154:291–297.
5.
LaviadesCVaroNFernandezJMayorGGilMJMonrealI. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation1998; 98:535–540.
6.
TimmsPMWrightAMaxwellPCampbellSDawnayABSrikanthanV.Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens2002; 15:269–272.
7.
AhmedSHClarkLLPenningtonWRWebbCSBonnemaDDLeonardiAH. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation2006; 113:2089–2096.
8.
LindsayMMMaxwellPDunnFG.TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension2002; 40:136–141.
9.
LopezBGonzalezAQuerejetaRLarmanMDiezJ.Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol2006; 48:89–96.
10.
CokerMLZellnerJLCrumbleyAJSpinaleFG.Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann N Y Acad Sci1999; 878:559.
11.
ReinhardtDSiguschHHHensseJTyagiSCKorferRFigullaHR.Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart2002; 88:525–530.
12.
SpinaleFGCokerMLHeungLJBondBRGunasingheHREtohT. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation2000; 102:1944–1949.
13.
LiYYFeldmanAMSunYMcTiernanCF.Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation1998; 98:1728–1734.
14.
OhtsukaTHamadaMSaekiHOgimotoAHaraYShigematsuY. Serum levels of matrix metalloproteinases and tumor necrosis factor-[alpha] in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol2003; 91:1024–1027.
15.
SundstromJArnlovJStolareKLindL.Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study. Heart2008; 94:874–878.
16.
DevereuxRBAlonsoDRLutasEMGottliebGJCampoESachsI. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol1986; 57:450–458.
17.
ThomasCVCokerMLZellnerJLHandyJRCrumbleyAJJrSpinaleFG.Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation1998; 97:1708–1715.
18.
PetersonJTHallakHJohnsonLLiHO'BrienPMSliskovicDR. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation2001; 103:2303–2309.
19.
LindseyMLGannonJAikawaMSchoenFJRabkinELopresti-MorrowL. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation2002; 105:753–758.
20.
ChanceyALBrowerGLPetersonJTJanickiJS.Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation2002; 105:1983–1988.
21.
McElmurrayJHJrMukherjeeRNewRBSampsonACKingMKHendrickJW. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther1999; 291:799.
22.
SpinaleFGCokerMLKrombachSRMukherjeeRHallakHHouckWV. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res1999; 85:364–376.
23.
RomanicAMHarrisonSMBaoWBurns-KurtisCLPickeringSGuJ. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res2002; 54:549–558.
24.
HeymansSLuttunANuyensDTheilmeierGCreemersEMoonsL. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med1999; 5:1135–1142.
25.
CreemersEEJMDavisJNParkhurstAMLeendersPDowdyKBHapkeE. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol2003; 284: H364–H371.
26.
IwanagaYAoyamaTKiharaYOnozawaYYonedaTSasayamaS.Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol2002; 39:1384–1391.
27.
SpinaleFGCokerMLThomasCVWalkerJDMukherjeeRHebbarL.Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res1998; 82:482–495.
28.
RouyDErnensIJeantyCWagnerDR.Plasma storage at −80°C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem2005; 338:294–298.
